Tipiracil HCl CAS# 183204-74-2 替吡嘧啶杂质
Tipiralacil, also known as TPI, is a thymidine phosphorylase inhibitor (TPI). Tipiracil is one of the active components in TAS-102, which is an anticancer drug candidate currently in clinical trials. TAS-102 consists of the cytotoxin Trifluridine and the thymidine phosphorylase inhibitor (TPI) tipiracil. Trifluridine is incorporated into DNA during DNA synthesis and inhibits tumor cell growth. Tipiracil protects trifluridine from being broken down when taken orally. TAS-102 was approved in Japan in 2015.
📌 参考资料/链接：
Ref: Maheta, Abhay Subodhbhai; Kaneria, Ankur Amrutlal; Bhesaniya, Kapil Dhanjibhai; Savaliya, Bhavesh Laljibhai; Koilpillai, Joseph Prabahar; Agarwal, Virendra Kumar; Chavan, Rahul Baburao; Arabiani, Mohsin Razakbhai; Hedapara, Kalpesh Ratilal; Katariya, Lalit Keshav; Patel, Vijay Premajibhai; Thummar, Mahesh Kurajibhai; Bhalodiya, Rahul Harsukhlal. Process for the preparation of tipiracil hydrochloride (Assignee Amneal Pharmaceuticals Company GmbH, Switz.). WO 2019002407 (2019).
Ref: Maheta, Abhay Subodhbhai; Kaneria, Ankur Amrutlal; Bhesaniya, Kapil Dhanjibhai; Savaliya, Bhavesh Laljibhai; Koilpillai, Joseph Prabahar; Agarwal, Virendra Kumar; Chavan, Rahul Baburao; Arabiani, Mohsin Razakbhai; Hedapara, Kalpesh Ratilal; Katariya, Lalit Keshav; Patel, Vijay Premajibhai; Thummar, Mahesh Kurajibhai; Bhalodiya, Rahul Harsukhlal. Process for the preparation of tipiracil hydrochloride (Assignee Amneal Pharmaceuticals Company GmbH, Switz.). WO 2019002407 (2019).
